Addex

Allosteric modulators for human health

  • About us
    • Addex Corporate Presentation
    • Overview
    • Our people
      • Executive Officers
      • Non-Executive Directors
      • Scientific Advisory Board
    • Contact
    • Privacy Policy
    • Careers
  • Pipeline
    • Clinical and Pre-Clinical Pipeline
    • Research And Development
  • Technology platform
    • Allosteric modulation
    • Our capabilities
      • Screening Assays
      • Chemistry
    • Publications
  • Partners & collaboration
  • Investors
    • Addex Corporate Presentation
    • Stock Data
    • Press releases
    • Ad hoc announcements (Art. 53 L.R)
    • Events
    • Financial Reports
    • Analyst Reports
    • General Meetings
    • SEC / SIX Filings
    • Guide to US ADSS for Six Shareholders
    • Register for email news
    • Corporate Governance
    • Contact
  • Media
    • Press releases
    • Contact
about us

about us

Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders.

Pipeline

Clinical and Pre-Clinical Pipeline

 

 

 

Research And Development

   

 

Publications
  • GABAB PAM for cough
  • M4 PAM for schizophrenia & other psychosis
  • ADX71149 for epilepsy
  • GABAB PAM for substance use disorder
  • Dipraglurant for post-stroke sensorimotor recovery
  • mGlu7 NAM for stress related disorders including PTSD
  • mGlu2 NAM for mild neurocognitive disorders
Placeholder image

Technology platform

Allosteric Modulation

Read more
Placeholder image

Partners & Collaborations

Industry

Read more

Latest news Latest news icon

  • 11.22
    2018

    Addex Van Leeuwenhoeck Equity Research Report Highlights Deep Pipeline Well Funded through Pivotal Registration Study and Increases Price Target to CHF 14

  • 11.12
    2018

    Addex to Present at the Biotech and Money Inv€$tival Showcase and Participate in the Jefferies London Healthcare Conference

  • 10.22
    2018

    Addex Selective mGlu2 PAM ADX71149 Included in Review Highlighting Promising Investigative Drugs for Epilepsy

  • 10.02
    2018

    Addex to Present at the Sachs 18th Annual Biotech in Europe Forum

  • 09.28
    2018

    Addex Reports 2018 Half-Year Financial Results and Provides Corporate Update

  • 09.25
    2018

    Addex to Present at the Investora Zurich Conference on 27 September

  • 09.25
    2018

    ADDEX THERAPEUTICS RECOGNISED IN FINAL SHORTLIST FOR DEAL OF THE YEAR AT LIFESTARS AWARDS LIFE SCIENCE AWARDS FOR PARTNERSHIP WITH INDIVIOR

  • 09.20
    2018

    Addex ADX10061 Receives £1.2 million Funding for Manufacture and Investigator Led Clinical Studies as part of the Tools for Human Drug and Brain Research (THuNDR2) Initiative from the Wellcome Trust

  • 09.04
    2018

    Addex’s Selective mGlu2 PAM ADX71149 Shows Promise in Treating Severe Panic Disorders and PTSD

  • 07.12
    2018

    Van Leeuwenhoeck Issues Equity Research Note Highlighting Addex Investment Opportunity

    Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • Next

Contact us

If you have any questions please let me know
  • Contact form
2026 © Addex therapeutics